Sundar Jagannath, MBBS, discusses CAR T-cell therapy considerations prior to initiation in the management of multiple myeloma.
Recent Content
- Evaluation of anti-CD38 monoclonal antibody-based immunotherapy in multiple myeloma with renal insufficiency: a systematic review and meta-analysis
- The FDA Grants ODD to OPN-6602 For Relapsed/Refractory Myeloma
- FDA Grants OPN-6602 Orphan Drug Destination for Treatment of Patients With Relapsed, Refractory Multiple Myeloma
- Author Correction: Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial
- Unexpected Support in Tough Times With Multiple Myeloma
- The AQUILA Debate: Daratumumab and Smoldering Multiple Myeloma
- Quadruple Therapy With Isatuximab Shows Promise for Older Adults With Multiple Myeloma
- Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis
- Myeloma cell-derived CXCL7 facilitates proliferation of tumor cells and occurrence of osteolytic lesions through JAK/STAT3 pathway
- VDAC2 primes myeloma cells for BAK-dependent apoptosis and represents a novel therapeutic target